Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
- 13 February 2008
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 19 (6), 1135-1140
- https://doi.org/10.1093/annonc/mdn013
Abstract
Background: This phase II study describes the efficacy and safety of combination chemotherapy of 5-fluorouracil (5-FU), low-dose leucovorin, and oxaliplatin (FLOX regimen) for pretreated advanced gastric cancer. Patients and methods: Patients who had been previously treated with greater than or equal to one regimen were enrolled. Patients received an oxaliplatin 75 mg/m2 on day 1, 5-FU 1000 mg/m2 on days 1–3, and leucovorin 20 mg/m2 on days 1–3, every 3 weeks. The primary end point was overall survival (OS). Results: Among the 52 patients enrolled, 26 patients were treated as second line, and the remaining 26 patients were enrolled as third- or fourth line. A total of 203 cycles of chemotherapy were administered with the median being three cycles (range 1–15) per patient. The median OS was 6.6 months [95% confidence interval (CI) 4.5–8.8] and the median progression-free survival was 2.5 months (95% CI 1.9–3.0). The response rate was 4% (95% CI 0–9%), and the disease control rate was 48% (95% CI 34–62%). The most common toxic effects of grade 3/4 were neutropenia (16%) and vomiting (6%). Conclusions: The FLOX regimen showed modest activity as a salvage treatment in pretreated advanced gastric cancer with a favorable compliance.Keywords
This publication has 21 references indexed in Scilit:
- A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patientsBritish Journal of Cancer, 2005
- Review of second-line chemotherapy for advanced gastric adenocarcinomaClinical Oncology, 2005
- Gastric cancer epidemiology and risk factorsJournal of Clinical Epidemiology, 2003
- Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric CancerJournal of Clinical Oncology, 1999
- Phase II study of paclitaxel in pretreated advanced gastric cancerAnti-Cancer Drugs, 1998
- Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell linesInvestigational New Drugs, 1997
- An Early Phase II Study of 5-Fluorouracil Combined with Cisplatinum as a Second Line Chemotherapy against Metastatic Gastric CancerJapanese Journal of Clinical Oncology, 1991
- Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexesChemico-Biological Interactions, 1989
- Cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC gastrointestinal tract cancer cooperative groupEuropean Journal of Cancer and Clinical Oncology, 1985
- Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancerAmerican Journal of Clinical Oncology, 1983